- Home
- CHRS vs GNFT Comparison
CHRS vs GNFT Comparison
Compare CHRS & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- GNFT
- Stock Information
- Founded
- CHRS 2010
- GNFT 1999
- Country
- CHRS United States
- GNFT France
- Employees
- CHRS 235
- GNFT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHRS Health Care
- GNFT Health Care
- Exchange
- CHRS Nasdaq
- GNFT Nasdaq
- Market Cap
- CHRS 134.4M
- GNFT 179.7M
- IPO Year
- CHRS 2014
- GNFT 2019
- Fundamental
- Price
- CHRS $1.21
- GNFT $3.91
- Analyst Decision
- CHRS Strong Buy
- GNFT Strong Buy
- Analyst Count
- CHRS 4
- GNFT 1
- Target Price
- CHRS $5.38
- GNFT $13.00
- AVG Volume (30 Days)
- CHRS 2.4M
- GNFT 9.9K
- Earning Date
- CHRS 03-12-2025
- GNFT 09-19-2024
- Dividend Yield
- CHRS N/A
- GNFT N/A
- EPS Growth
- CHRS N/A
- GNFT N/A
- EPS
- CHRS N/A
- GNFT 0.47
- Revenue
- CHRS $304,340,000.00
- GNFT $86,225,222.00
- Revenue This Year
- CHRS $2.47
- GNFT $145.20
- Revenue Next Year
- CHRS N/A
- GNFT N/A
- P/E Ratio
- CHRS N/A
- GNFT $7.89
- Revenue Growth
- CHRS 44.19
- GNFT 175.45
- 52 Week Low
- CHRS $0.66
- GNFT $3.35
- 52 Week High
- CHRS $2.87
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- CHRS 44.03
- GNFT 54.95
- Support Level
- CHRS $1.03
- GNFT $3.68
- Resistance Level
- CHRS $1.23
- GNFT $3.96
- Average True Range (ATR)
- CHRS 0.13
- GNFT 0.13
- MACD
- CHRS -0.02
- GNFT 0.05
- Stochastic Oscillator
- CHRS 38.89
- GNFT 79.49
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.